AU2021233433A1 - Crystal of imidazopyridinone compound or salt thereof - Google Patents

Crystal of imidazopyridinone compound or salt thereof Download PDF

Info

Publication number
AU2021233433A1
AU2021233433A1 AU2021233433A AU2021233433A AU2021233433A1 AU 2021233433 A1 AU2021233433 A1 AU 2021233433A1 AU 2021233433 A AU2021233433 A AU 2021233433A AU 2021233433 A AU2021233433 A AU 2021233433A AU 2021233433 A1 AU2021233433 A1 AU 2021233433A1
Authority
AU
Australia
Prior art keywords
peaks
compound
crystal
crystal form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021233433A
Other languages
English (en)
Inventor
Yoshiro KIJIMA
Akihiro Moriyama
Hideki Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of AU2021233433A1 publication Critical patent/AU2021233433A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2021233433A 2020-03-11 2021-03-10 Crystal of imidazopyridinone compound or salt thereof Pending AU2021233433A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-041453 2020-03-11
JP2020041453 2020-03-11
PCT/JP2021/009405 WO2021182490A1 (ja) 2020-03-11 2021-03-10 イミダゾピリジノン化合物又はその塩の結晶

Publications (1)

Publication Number Publication Date
AU2021233433A1 true AU2021233433A1 (en) 2022-10-06

Family

ID=77672382

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021233433A Pending AU2021233433A1 (en) 2020-03-11 2021-03-10 Crystal of imidazopyridinone compound or salt thereof

Country Status (8)

Country Link
US (1) US20230167108A1 (https=)
EP (1) EP4091670A4 (https=)
JP (1) JP7566008B2 (https=)
KR (1) KR20220152276A (https=)
CN (1) CN115279761B (https=)
AU (1) AU2021233433A1 (https=)
CA (1) CA3169000A1 (https=)
WO (1) WO2021182490A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
US20070142369A1 (en) * 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2696725A1 (en) * 2007-08-10 2009-03-26 Crystalgenomics, Inc. Pyridine derivatives and methods of use thereof
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
EP2285375B1 (en) 2008-05-08 2013-04-10 Merck Sharp & Dohme Corp. spiroazaindole compounds as HIF propylhydroxylase inhibitors
SI2455381T1 (sl) * 2009-07-17 2014-08-29 Japan Tobacco Inc. Triazolopiridinova spojina in njeno delovanje kot zaviralec prolil-hidroksilaze in induktor produkcije eritropoietina
EP3698794A1 (en) * 2009-11-06 2020-08-26 Aerpio Therapeutics, Inc. Compositions and methods for treating colitis
WO2014181813A1 (ja) * 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
JP7458987B2 (ja) * 2018-09-13 2024-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物

Also Published As

Publication number Publication date
US20230167108A1 (en) 2023-06-01
JPWO2021182490A1 (https=) 2021-09-16
KR20220152276A (ko) 2022-11-15
CN115279761A (zh) 2022-11-01
CA3169000A1 (en) 2021-09-16
EP4091670A1 (en) 2022-11-23
JP7566008B2 (ja) 2024-10-11
CN115279761B (zh) 2025-03-14
WO2021182490A1 (ja) 2021-09-16
EP4091670A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
KR102705376B1 (ko) 화학적 화합물
CN114907387A (zh) 嘧啶并吡咯类kras抑制剂及其制备方法与应用
CN104797581B (zh) 杂芳基炔烃化合物及其应用
UA109660C2 (xx) Заміщені 5-фтор-1h-піразолопіридини та їх застосування
CN111132984A (zh) 凋亡信号调节激酶1抑制剂的盐及其晶型
TW202421129A (zh) 用作 cdk4 激酶抑制劑的化合物及其應用
CN112313233A (zh) Jak家族激酶的小分子抑制剂
WO2023118576A1 (en) Dhodh inhibitors containing a carboxylic acid bioisostere
AU2021233433A1 (en) Crystal of imidazopyridinone compound or salt thereof
CN104334528A (zh) (2-杂芳基氨基)琥珀酸衍生物
WO2025051211A1 (zh) 用作cdk4激酶抑制剂的化合物及其应用
WO2025108336A1 (zh) 用于egfr蛋白降解的化合物及其用途
JP2019504054A (ja) キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途
CA3252402A1 (en) COMPOUND USED AS A FAK INHIBITOR AND ITS USE
CA3096341C (en) 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy
TW202237101A (zh) Ｃｔｌａ－４小分子降解劑及其應用
CN115286626A (zh) 作为外周nmda受体拮抗剂的新型地佐环平衍生物
HK40083277A (en) Crystal of imidazopyridinone compound or salt thereof
CN115244054B (zh) 次黄嘌呤化合物的晶体
CN117343064B (zh) 一种具有抗病毒作用的嘧啶衍生物的制备与应用
KR102959367B1 (ko) Ep4 길항제 화합물, 이의 염, 다형체 및 용도
CN104321318A (zh) 4-烷酰基氨基-3-吡唑啉酮衍生物
US20240368088A1 (en) Ep4 antagonist compound as well as salt, polymorph and use thereof
CN110950773B (zh) 联苯二酚酰胺衍生物及其作为抗癌药物的应用
RU2800292C2 (ru) Химические соединения